Sei Investments Co. Decreases Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Sei Investments Co. reduced its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 41.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,601 shares of the biopharmaceutical company's stock after selling 9,568 shares during the quarter. Sei Investments Co.'s holdings in Agios Pharmaceuticals were worth $447,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. State Street Corp raised its stake in Agios Pharmaceuticals by 10.2% in the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock valued at $103,586,000 after acquiring an additional 216,484 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Agios Pharmaceuticals by 15.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock worth $531,000 after buying an additional 1,570 shares during the last quarter. FMR LLC boosted its stake in shares of Agios Pharmaceuticals by 283.2% in the 3rd quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock valued at $2,017,000 after purchasing an additional 33,546 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth $33,000. Finally, Franklin Resources Inc. acquired a new position in Agios Pharmaceuticals in the 3rd quarter worth about $1,499,000.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock traded up $0.24 during trading hours on Tuesday, reaching $27.76. The company's stock had a trading volume of 128,743 shares, compared to its average volume of 708,379. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The stock has a market cap of $1.59 billion, a P/E ratio of 2.45 and a beta of 0.83. The firm has a 50 day moving average price of $31.25 and a 200-day moving average price of $39.06.

Remove Ads

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective on the stock. StockNews.com downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of "Hold" and a consensus price target of $56.57.

Insider Buying and Selling

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.93% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.